GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Diabetes

• Publication date

  2014-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/db14-0849PMID 25071023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of GLP-1 on appetite and body weight : focus on the central nervous system Chapter 2

  2015influential reference
• Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.

  2014cited by this paper
• Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.

  2014cited by this paper
• Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

  2014cited by this paper
• The regulation of food intake by the gut-brain axis: implications for obesity

  2013cited by this paper
• Obesity and addiction: neurobiological overlaps

  2013cited by this paper
• A link between FTO, ghrelin, and impaired brain food-cue responsivity.

  2013cited by this paper
• Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies.

  2012influential reference
• Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.

  2012cited by this paper
• The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors

  2012cited by this paper
• fMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program

  2012influential reference
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012influential reference
• The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans

  2011cited by this paper
• IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

  2011cited by this paper
• Attentional Bias to Food Images Associated With Elevated Weight and Future Weight Gain: An fMRI Study

  2011cited by this paper
• Peptide hormones regulating appetite—focus on neuroimaging studies in humans

  2011cited by this paper
• Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

  2011cited by this paper
• Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

  2011cited by this paper
• Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

  2009cited by this paper
• Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.

  2008cited by this paper
• Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans

  2008cited by this paper
• Widespread reward-system activation in obese women in response to pictures of high-calorie foods

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Dissociating the Role of the Orbitofrontal Cortex and the Striatum in the Computation of Goal Values and Prediction Errors

  2008cited by this paper
• Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli.

  2008influential reference
• Ghrelin modulates brain activity in areas that control appetitive behavior.

  2008cited by this paper
• Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans

  2007cited by this paper
• Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals

  2007influential reference
• Orbitofrontal cortex and its contribution to decision-making.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

  2005cited by this paper
• The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway.

  2005cited by this paper
• The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: Depressed and Positive Affect in cancer patients and healthy reference subjects

  2004cited by this paper
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

  2004cited by this paper
• Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length.

  2004influential reference
• Images of desire: food-craving activation during fMRI

  2004cited by this paper
• Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration

  2004cited by this paper
• Cortical and limbic activation during viewing of high- versus low-calorie foods

  2003cited by this paper
• Appetitive Behavior

  2003cited by this paper
• IL‐6 Modulates Hyperglycemia‐Induced Changes of Na+ Channel Beta‐3 Subunit Expression by Schwann Cells

  2003cited by this paper
• Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

  2003cited by this paper
• Entry of exendin-4 into brain is rapid but may be limited at high doses

  2003cited by this paper
• Dissociation of neural representation of intensity and affective valuation in human gustation.

  2003cited by this paper
• The amygdala and reward

  2002cited by this paper
• A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

  2001influential reference
• Glucagon-like peptide-1.

  2001cited by this paper
• Changes in brain activity related to eating chocolate: from pleasure to aversion.

  2001influential reference
• The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings

  2000cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide.

  1995cited by this paper
• De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS).

  1990influential reference
• Scoring the eating disorder inventory.

  1986cited by this paper

• Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage.

  2026cites this paper
• Future Prospects of GLP-1–Based Biopharmaceuticals in Obesity and Diabetes Management: A Food and Biotechnology Perspective

  2026cites this paper
• Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study.

  2026cites this paper
• Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap

  2026cites this paper
• Quieting "Food Noise": How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits

  2026cites this paper
• Efficacy And Safety of Semaglutide In Non-Diabetic Adults With Overweight Or Obesity: A Meta-Analysis Of Randomized Controlled Trials.

  2026cites this paper
• Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management

  2026cites this paper
• Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases

  2026cites this paper
• Neuropsychiatrische Effekte von GLP-1-Rezeptor-Agonisten

  2026cites this paper
• Navigating the Psychosocial Aspects in Diabetes

  2026cites this paper
• Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

  2026cites this paper
• Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

  2026cites this paper
• The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome.

  2025cites this paper
• Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?

  2025cites this paper
• Post-bariatric surgery quality-of-life decline: analysis of the gut–brain axis

  2025cites this paper
• The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

  2025cites this paper
• The expanding role of semaglutide: beyond glycemic control

  2025cites this paper
• Semaglutide and Taste in Women with Obesity and Polycystic Ovary Syndrome: a Randomized Placebo-Controlled Study.

  2025cites this paper
• Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study

  2025cites this paper
• A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior

  2025cites this paper
• Psychometric evaluation of the Adult Eating Behavior Questionnaire and its relationship with body mass index among Chinese university students: a cross-sectional validation study

  2025cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry

  2025cites this paper
• Glucagon-like peptide-1, fibroblast growth factor 21, and other endocrine responses to alcohol ingestion in women before and after metabolic surgery

  2025cites this paper
• Effect of dietary stimulation on acute changes in GLP-1, alcohol responses, craving, and attentional bias: a randomized, placebo-controlled laboratory study.

  2025cites this paper
• The GLP-1R Agonist Semaglutide Reduces Motivated Running and Alters Dopamine Dynamics in the Nucleus Accumbens

  2025cites this paper
• Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity

  2025cites this paper
• Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence

  2025cites this paper
• A Case of Paradoxical Appetite Increase During Semaglutide Therapy

  2025cites this paper
• Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial

  2025cites this paper
• Systematic review of hypoglycemic polysaccharides: sources, preparation, and identification techniques, evaluation models, structure–activity relationships, and mechanistic insights

  2025cites this paper
• A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.

  2025cites this paper
• Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review

  2025cites this paper
• Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

  2025cites this paper
• The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes.

  2025cites this paper
• Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs

  2025cites this paper
• Effect of GLP-1 receptor agonists on body composition.

  2025cites this paper
• The (dys)regulation of energy storage in obesity.

  2025cites this paper
• Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study

  2025cites this paper
• Sex-specific signatures of GLP-1 and amylin on resting state brain activity and functional connectivity in awake rats.

  2025cites this paper
• Insulin Resistance: The Role in Comorbid Type 2 Diabetes Mellitus and Depression.

  2025cites this paper
• Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database

  2025cites this paper
• The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention

  2025cites this paper
• GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

  2025cites this paper
• Domain‐Specific and Domain‐General Functional Brain Alterations in Type 2 Diabetes Mellitus: A Task‐Based and Functional Connectivity Meta‐Analysis

  2025cites this paper
• Depressive symptoms at short‐, medium‐, and long‐term follow‐up after bariatric surgical procedures: A systematic review and meta‐analysis

  2025cites this paper
• GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential

  2025cites this paper
• Associations between eating behaviours and psychological characteristics with BMI change and appetite-related changes during incretin-based therapy.

  2025cites this paper
• The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery

  2025cites this paper
• Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape

  2025cites this paper
• 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026.

  2025cites this paper
• Insights into the mechanisms of body weight control.

  2025cites this paper
• One Year of Exercise After Weight Loss Increases Postprandial GLP‐1 Secretion in Contrast to Usual Activity or GLP‐1 Receptor Agonist Treatment

  2025cites this paper
• Determinants of adherence to obesity medication: A narrative review

  2025cites this paper
• Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size

  2025cites this paper
• Obesity: a disease of the ponderostat and the regulation of energy balance

  2025cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review

  2025cites this paper
• Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.

  2025cites this paper
• Narrative review on glucagon-like peptide-1 receptor agonists and late-life depression: a new frontier in geriatric psychiatry?

  2025cites this paper
• GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective

  2025cites this paper
• Novel zwitterionic densely charged neutral sulfobetaine polymeric micelles for oral delivery of therapeutic peptides: a proof-of-concept study

  2025cites this paper
• Glucagon‐like peptide‐1 analogues reduce alcohol intake

  2025cites this paper
• Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder

  2025cites this paper
• Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review

  2025cites this paper
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review

  2025cites this paper
• GLP-1 agonists: a game changer in pain treatment and addiction.

  2025cites this paper
• Goal Integration of Diabetes Self-Management Education and Psychosocial Support With Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes and Obesity.

  2025cites this paper
• Neurovascular decoupling of frontoparietal cortex-putamen-cerebellum network in type 2 diabetes patient: Potential biomarker for abnormal eating patterns.

  2025cites this paper
• Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.

  2024cites this paper
• Metabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates

  2024cites this paper
• Meta‐analysis on GLP‐1 mediated modulation of autophagy in islet β‐cells: Prospectus for improved wound healing in type 2 diabetes

  2024cites this paper
• Comparative Effects of GLP-1 and GLP-2 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation

  2024cites this paper
• 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025.

  2024cites this paper
• Functional reorganization of memory processing in the hippocampus is associated with neuroprotector GLP-1 levels in type 2 diabetes

  2024cites this paper
• Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities

  2024cites this paper
• GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm

  2024cites this paper
• Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats

  2024cites this paper
• Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review

  2024cites this paper
• Treatment of Hypothalamic Obesity With GLP-1 Analogs

  2024cites this paper
• Glucagon‐like pepetide‐1 receptor agonist suggests novel therapeutic options for hypothalamic obesity

  2024cites this paper
• Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists

  2024cites this paper
• Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD)

  2024cites this paper
• Obesity surgery and neural correlates of human eating behaviour: A systematic review of functional MRI studies

  2024cites this paper
• Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions

  2024cites this paper
• A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists

  2024cites this paper
• Comfort Foods in the Twenty-First Century: Friend or Foe?

  2024cites this paper
• Perioperative management of patients on glucagon-like peptide-1 receptor agonists.

  2024cites this paper
• The glucagon‐like peptide‐1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery

  2024cites this paper
• GLP-1 programs the neurovascular landscape.

  2024cites this paper
• Jiang Tang San Hao Formula exerts its anti-diabetic effect by affecting the gut-microbiota-brain axis.

  2024cites this paper
• The Contribution of the Brain–Gut Axis to the Human Reward System

  2024cites this paper
• Feeding gut microbes to nourish the brain: unravelling the diet–microbiota–gut–brain axis

  2024cites this paper
• Medicatie voor obesitas: vooruitgang en uitdagingen

  2024cites this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cites this paper
• Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs

  2024cites this paper
• Reward and Inhibitory Control as Mechanisms and Treatment Targets for Binge Eating Disorder

  2024cites this paper
• Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials

  2024cites this paper
• Humulus lupulus L.: Evaluation of Phytochemical Profile and Activation of Bitter Taste Receptors to Regulate Appetite and Satiety in Intestinal Secretin Tumor Cell Line (STC-1 Cells).

  2024cites this paper
• Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes

  2024cites this paper
• Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease

  2024cites this paper
• Semaglutide and obesity: beyond the nutritional and lifestyle intervention?

  2024cites this paper